KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial.

Anuja Dokras, Christos Coutifaris, Alan T Remaley, Nehal N Mehta, Martin P Playford, Allen R Kunselman, Christy C Stetter, William C Dodson, Richard S Legro

PLoS Med 22(12) e1004662

PMID41359669
PMCIDPMC12697981
DOI10.1371/journal.pmed.1004662
发表日期2025-12-08
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:AI 判定为 other。
摘要

摘要

BACKGROUND: The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of these first-line medications on cardiovascular disease (CVD) risk, we compared the effect of COCPs, metformin or both on prevalence of metabolic syndrome (MetS) in participants with hyperandrogenic PCOS and hypothesized that COCPs would increase prevalence of MetS while metformin would decrease prevalence of MetS. METHODS AND FINDINGS: We conducted a multicenter, double-blind, double-dummy, randomized trial (COMET-PCOS) in participants between ages ≥18 and ≤40 years and body mass index (BMI) ≥25 kg/m2 and ≤ 48 kg/m2 with hyperandrogenic PCOS (defined by the Rotterdam criteria). Participants were randomized 1:1:1 to 24 weeks of low-dose COCPs (20 μg ethinyl estradiol/0.15 mg desogestrol), metforminXR (2,000 mg), or both (Combined). The primary outcome, assessed by intention-to-treat analysis, was the effect of the different treatment groups on the prevalence of MetS at the end of study. The analytical model included site, race, and the presence or absence of MetS at the screening visit as covariates. The secondary outcomes included changes in each component of MetS (TG, HDL-C, BP, WC, and fasting glucose levels) over the study period. Of the 240 participants randomly assigned, 20 out of 79 in the COCP group, 16 out of 81 in the metformin group, and 17 out of 80 in the combined group dropped out of the study. A total of 169 participants (70.4%) completed the trial between January 2018 and June 2023 (mean age: 29.5 years; mean BMI: 35.6 kg/m2; 70% were White and 23% were Black). The overall prevalence of MetS was 31% at baseline and comparable across groups. At the end of the study, the prevalence of MetS was 26.2% (17/65) in the metformin group, 28.6% (17/59) in the Combined group, and 28.8% (17/59) in COCP group with no significant difference in trend of MetS prevalence between groups (adjusted p = 0.26). Waist circumference (mean change (MC) -2.23 cm; 95% CI [-3.98, -0.49]; p = 0.01), BMI (MC -0.49 kg/m2; 95% CI [-0.88, -0.10]; p = 0.01), and android fat mass measured by DXA (MC -167 g; 95% CI [-264, -71[; p < 0.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. In the metformin and Combined groups, the majority of participants (>64%) reported diarrhea, while 24.1% in the COCP group reported uterine bleeding. The main methodologic limitation of the study is the potential lack of power to detect differences in secondary outcomes. CONCLUSIONS: In participants with hyperandrogenic PCOS and overweight/obesity, low-dose COCPs effectively managed PCOS symptoms without increasing prevalence of MetS. Our findings challenge the current practice of using metformin alone or with COCPs for lowering cardiometabolic risk. TRIAL REGISTRATION: ClinicalTrials.Gov Identifier: NCT03229057.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1. Trial participant flow chart for COMET PCOS trial with participants randomized to continuous oral contraceptive pills (COCP), extended-release metformin (Metformin XR), or both (COCP + metformin XR).
非 KM Figure
Fig 2Fig 2. Metabolic syndrome and individual components at baseline and end of study. Panel A shows the change in prevalence of MetS between baseline values (pre) and at the end of study (post) in the combined oral contraceptive pills (COCP) group, metformin group, and combined group. MetS was defined as presence of at least 3 of the following 5 criteria: TG ≥150 mg/dl, HDL-C <50 mg/dl, BP ≥130/ ≥ 85 mmHg or use of anti-hypertensive medications, waist circumference ≥88 cm (≥80 cm for Asian participants), and fasting glucose ≥100 mg/dl. Panels B – F show the change in prevalence of abnormal criterion for individual components of MetS. P -values for significant differences within and between groups are displayed; the significant differences in the change (pre to post) between groups are denoted with an asterisk. Error bars represent the 95% confidence interval (CI) for the proportion. Estimates for these proportions, 95% CIs, and p -values for comparisons, were obtained via binary logistic regression to account for repeated measurements per subject and using GEE adjusting for race (Black/non-Black) and recruitment site (Penn/PSU).
非 KM Figure